Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 7/20 | 0.47 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methionine SCHEMBL27647161 | 0.88 | RNPEP (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL27686953 | 0.88 | BHMT (0.53) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL126688 | 0.88 | — | — | |
| Racemethionine SCHEMBL9504290 | 0.88 | — | — | |
| Racemethionine SCHEMBL16062299 | 0.88 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL23361954 | 0.88 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL5584463 | 0.88 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL4226 | 0.88 | — | — | |
| Racemethionine SCHEMBL287590 | 0.88 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL5617580 | 0.88 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | BHMT 1839/4885BHMT2 3343/4885RNPEP 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.